Composite Lymphoma Comprising Follicular Lymphoma with In-situ Mantle Cell Neoplasia: A Case Report and Review of the Literature
AbstractA 55-year-old gentleman presented to our hospital with a single inguinal adenopathy, and no other clinical symptoms or signs. An excisional lymph node biopsy was performed. Pathologic evaluation demonstrated follicular center site which stained positive for CD20, CD10, Bcl-2, Bcl-6, and mantle zone cells which demonstrated Cyclin D1 (CCND1) positivity, partial SOX11 positivity and no expression of CD5, suggesting the diagnosis of composite lymphoma comprising follicular lymphoma (FL) with in situ mantle cell neoplasia (ISMCN), the latter previously referred as in situ mantle cell lymphoma (MCLIS). FL is known as indolent non-Hodgkin lymphoma; however, the clinical significance of a coexisting ISMCN continues to be elusive, and optimal management of these patients remains largely unknown. This paper reports a new case of this extremely uncommon condition and also discusses reviews of the literature including advances in molecular pathogenesis and lymphoma genomics with the aim to offer novel insights into this rare hematological malignancy.
Kim H. Composite lymphoma and related disorders. Am J Clin Pathol. 1993;99:445-451.
Wang E, Papavassiliou, Wang AR, et al. Composite lymphoid neoplasm of B-cell and T-cell origins: a pathologic study of 14 cases. Hum Pathol. 2014;45:768-784.
Wang S, Tzankov A, Xu-Monette ZY, et al. Clonally related composite follicular lymphoma and mantle cell lymphoma with clinicopathologic features and biological implications. Hum Pathol. 2013;44:2658-2667.
Taverna J, Nair A, Yun S, et al. A rare presentation of in situ mantle cell lymphoma and follicular lymphoma: a case report and review of the literature. Case Rep Hematol. 2014;2014:145129.
Subtil A, Xu Z. Follicular lymphoma with composite in situ mantle cell neoplasia. Blood. 2019; 133(22):2460. https://doi.org/10.1182/blood.2019000012 10.1182/blood.2019000012
Hsi ED. 2016 WHO Classification update-What's new in lymphoid neoplasms. Int J Lab Hematol. 2017;Suppl1:14-22.
Carvajal-Cuenca A, Sua LF, Silva NM, et al., “In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior.” Haematologica. 2012;97;2:270–278.
Adam P, Katzenberger T, Eifert M,et al. Presence of preserved reactive germinal centers in follicular lymphoma is a strong histopathologic indicator of limited disease stage. Am J Surg Pathol. 2005;29(12):1661-1664.
Cong P, Raffeld M, Teruya-Feldstein J, et al. In situ localization of follicular lymphoma: description and analysis by laser capture microdissection. Blood. 2002;1;99(9):3376-3382.
Jegalian AG, Eberle FC, Pack SD, et al. Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. Blood. 2011;118(11):2976-2984.
Lecluse Y, Lebailly P, Roulland S,et al. t(11;14)-positive clones can persist over a long period of time in the peripheral blood of healthy individuals. Leukemia. 2009;23(6):1190-1193.
Racke F, Simpson S, Christian B, et al. American Society of Hematology. Evidence of long latency periods prior to development of mantle cell lymphoma. [Abstract]; 2010; San Diego, CA. 2010
Espinet B, Sole F, Pedro C, et al. Clonal proliferation of cyclin D1-positive mantle lymphocytes in an asymptomatic patient: an early-stage event in the development or an indolent form of a mantle cell lymphoma? Hum Pathol. 2005;36(11):1232-1237.
Miyazawa Y, Yokohama A, Ishizaki T, et al. Pathological and molecular analysis of a composite lymphoma of mantle cell lymphoma and Epstein-Barr virus-positive follicular lymphoma. Int J Hematol. 2021;113(4):592-599.
P. Hsu, T. Yang, S. Sheikh-Fayyaz, et al. Mantle cell lymphoma with in situ or mantle zone growth pattern: a study of five cases and review of literature. Int J Clin Exp Pathol. 2014;7;3: 1042–1050.
Copyright (c) 2022 Antonio Lapenna, Antonella Bianchi, Ombretta Annibali, Valeria Tomarchio, Silvia Maria Rossi, Giuseppe Perrone
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).